Possible scenario
Regulatory Path Clarifies
23% Chance
Following the FDA's expanded use of AI and UpDoc AI's approval, regulators give hospitals clearer expectations for deploying clinical AI tools. Healthleap benefits if guidance distinguishes workflow automation from higher-risk diagnostic software, but faces delays if oversight broadens.
Secondary impacts
- Technology +0.1%
- Healthcare +0.1%
Portfolio impact
S&P 500+0.1%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.